Sapna Bhatia, MD
Pulmonary Disease · Henderson, NVNPI 1619139813
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,210 of the $9,604 with a category attached, or 75.1%. 23 manufacturers reported payments, led by Intuitive Surgical at 27.8% of the total. Reporting peaked in 2022 at $3,471 and has fallen 96.0% since, to $139 in 2025.
Across 231 payments — averaging $41.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Electromed, Inc.$2K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$760
- Amgen$630
- United Therapeutics Corporation$496
- plus $2K from 17 others
What the payments were for
- Travel & lodging$2,22523%
- Food & beverage$7,21075%
- Education$1692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $2,671 |
| Electromed, Inc. | 43 | $1,688 |
| AstraZeneca | 30 | $1,106 |
| Actelion Pharmaceuticals US, Inc. | 29 | $760 |
| Amgen | 38 | $630 |
| United Therapeutics Corporation | 6 | $496 |
| Veran Medical Technologies, Inc. | 5 | $490 |
| Mylan Specialty L.p. | 15 | $399 |
| Boehringer Ingelheim | 5 | $289 |
| GSK | 10 | $207 |
| Axsome Therapeutics, Inc. | 6 | $156 |
| Boston Scientific | 3 | $154 |
| Baxter Healthcare | 5 | $144 |
| Harmony Biosciences LLC | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Exelixis Inc. | 1 | $50 |
| Olympus America Inc. | 2 | $49 |
| Bayer | 1 | $48 |
| Philips North America LLC | 2 | $35 |
| Inogen, Inc. | 3 | $26 |
| Breas Medical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,604 in reported general payments places this provider in the 75th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 32 | $404,453 |
| OfevNintedanib Esylate | 28 | $366,550 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 269 | $197,820 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 114 | $84,714 |
| Spiriva RespimatTiotropium Bromide | 95 | $48,746 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $35,952 |
| EliquisApixaban | 24 | $13,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,243 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,341 |
| Arnuity ElliptaFluticasone Furoate | 23 | $6,155 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,346 |
| Advair DiskusFluticasone Propion/Salmeterol | 17 | $4,788 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,177 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $3,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 169 | $3,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $289 | $415,296123 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $760 | $404,45332 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $207 | $254,346404 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,106 | $90,061127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Henderson
- Cyriac ChemplavilHenderson$18K
- Thomson ChemplavilHenderson$17K
- Rajiv AmesurHenderson$9K
- Robert WillsHenderson$8K
- Syed AkbarullahHenderson$4K
- Michelle DanielianHenderson$2K
- Xenia SchneiderHenderson$805
- Hrishikesh KulkarniHenderson$606
- Kenneth MooneyHenderson$500
- James HsuHenderson$461
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.